RNL Bio, global leader in adult stem cell therapeutics, announced on April 30th that the Korean FDA approved its human clinical study to treat patients with spinal cord injury using ‘RNL-Astrostem’
RNL Bio presented its three years’ preclinical trial results showing perfect safety profile and remarkable efficacy potential. RNL was approved to begin phase I human trial using these adult stem cells and it is the world first trial to treat spinal cord injury with adult stem cells derived patients’ own fat tissue.
RNL-Astrostem is administered by intravenous infusion so patients don’t have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of the firm, said “Our stem cell therapeutics involves no immune rejection because the stem cells are exactly patients own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed safest therapeutics to help devastated patients with incurable diseases."
RNL Bio already launched commercial stem cell therapy for pets like dogs and cats with spinal cord injury since 2008
